A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer

Annals of Oncology

Volumn 11, Issue 10, 2000, Pages 1267-1272

  Oettle, H ^a   Arning, M ^b   Pelzer, U ^a   Arnold, D ^a   Stroszczynski, C ^a   Langrehr, J ^a   Reitzig, P ^c   Kindler, M ^d   Herrenberger, J ^d   Musch, R ^e   Korsten, F W ^f   Huhn, D ^a   Riess, H ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c MARTIN LUTHER KRANKENHAUS   (Germany)

^d Onkologische Schwerpunktpraxis   (Germany)

^e Vivantes Wenckebach Klinikum   (Germany)

^f Krankenhaus   (Germany)

Author keywords

5 FU; Chemotherapy; Folinic acid; Gemcitabine; Oemzar ; Pancreas cancer

Indexed keywords

FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; MALE; PANCREAS CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0033768608     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008364018881     Document Type: Article

References (43)

1. Cancer of the pancreas
2. Cancer statistics
3. Treatment of advanced and metastatic pancreatic cancer
4. Chemotherapy in the treatment of cancer of the pancreas
5. Possibilities of palliation in pancreatic cancer
6. Practical recommendations for the management of adenocarcinoma of the pancreas
7. Current chemotherapeutic possibilities in pancreaticobiliary cancer
8. Chemotherapy of gastrointestinal cancer
9. Continuous 5-fluorouracil infusion in carcinoma of the pancreas
10. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial
11. Chemotherapy for pancreatic carcinoma
12. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin and mitomycin
13. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin and mitomycin (FAM), with 5-fluorouracil, streptozocin znd mitomycin (FSM)
14. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluation of the Mallinson regimen and combined 5-fluorouracil, doxorubicin and cisplatin
15. A phase III comparison trial of streptozocin, mitomycin and fluorouracil with cisplatin, cytosine arabinoside and caffeine in patients with advanced pancreatic carcinoma
16. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenoma of the pancreas
17. Phase II study of gemcitabine in patients with advanced pancreatic cancer
18. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
19. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
20. Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil
21. Inhibition of ribonucleotide reductase in CCRF-CEM cells by 2',2'difluorodeoxycytidine
22. Phase I trial of gemcitabine (Gemzar®), 24-hour infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
23. UICC TNM Classification of Malignant Tumors, 5th edition
24. Gemcitabine (GEM) and continuous infusion fluorouracil (CIF): A phase II study in advanced pancreatic cancer (APC)
25. Phase II trial of the use of gemcitabine (G) and 5-fluorouracil (5-FU) in the treatment of advanced pancreatic (APC) and biliary tract (ABTC) adenocarcinoma
26. Gemcitabine (GEM) plus 5-fluorouracil (5-FU) modulated by leucovorin (LV) for advanced pancreatic cancer
27. Multicenter phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5-FU bolus and infusion, and gemcitabine (FOLFUGEM regimen)
28. Phase I-II study of gemcitabine (GEM) and weekly 48-hour continuous infusion (CI) high-dose 5-fluorouracil (5-FU) in advanced exocrine pancreatic cancer (APC)
29. A phase I study of gemcitabine (GEM) in combination, with five days 5-fluouracil (5-FU) and folinic acid (FA) in patients with advanced adenocarcinoma of pancreas or bile duct
30. A phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer
31. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GIS-CAD)
32. Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer
33. Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer: Final results of a phase II study
34. Randomized trial of gemcitabine (GEM) alone or with cisplatin (CDDP) in the treatment of advanced pancreatic cancer (APC): A phase II multicenter study of the Southern Italy Oncology Group
35. First-line treatment with docetaxel (D) and gemcitabine (G) in patients with a advanced pancreatic cancer: A multicenter phase II study
36. Gemcitabine (G) and Taxotere (T) in patients with unresectable pancreatic carcinoma
37. Phase I study of a treatment with gemcitabine and docetaxel weekly in advanced pancreatic cancer
38. Dose-finding study of gemcitabine and epirubicin in patients with advanced pancreatic cancer
39. Phase II trials of gemcitabine, epirubicin, and G-CSF in patients with metastatic pancreatic cancer
40. PEF-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine): A new combination in advanced pancreatic adenocarcinoma. Phase II study
41. High inter- and intra-patient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion
42. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: Results of a multicentric prospective trial of fluorouracil dosage optimisation by pharmacokinetic monitoring in 152 patients